CHOP plus L-asparaginase for Patients with Peripheral T-cell Lymphoma

CHOP合併L-asparaginase對於周邊T細胞淋巴瘤的療效評估

張育誠(Yu-Cheng Chang) ； 蘇迺文(Nai-Wen Su) ； 鄭弘毅(Hong-Yi Zheng) ； 林煥超(Huan-Chao Lin) ； 林建鴻(Jian-Hong Lim) ； 張義芳(Yi-Fang Chang) ； 林炯森(Johnson Lin) ； 謝瑞坤(Ruei-Kun Hsie) ； 張明志(Ming-Chin Chang) ； 陳功深(Gon-Shen Chen)

《台灣癌症醫學雜誌》 27卷3期 (2011/06) Pp. 93-99

https://doi.org/10.6323/JoCRP.2011.27.3.1

摘要

背景：希望能發展出可被廣泛接受的周邊T細胞淋巴瘤的化療處方。方式：2008年7月至2010年12月共七位周邊T細胞淋巴瘤的患者，接受CHOP合併L-asparaginase作為第一線化學治療處方。治療方法為傳統的CHOP處方合併L-asparaginase每體表面積6000單位共使用五天，每三週施打一次。結果：七位患者都能忍受合併處方的治療，其中兩位患者疾病穩定，另外五位疾病完全緩解，但有兩位患者分別在五個月及一年後復發。A-CHOP治療反應率高達七成。化學治療期間並沒有出現凝血功能障礙或出血傾向。結論：病人對A-CHOP治療有好的耐受力，但L-asparaginase的效果仍待更多的臨床試驗證實。

關鍵字

L-asparaginase ； T細胞淋巴瘤 ； 化療處方

並列摘要

Background: Our aim here was to contribute toward development of a broadly accepted treatment regimen for peripheral T-cell lymphoma.Methods: Seven patients were diagnosed as peripheral T cell lymphoma in our institution from July 2008 to December 2010. They received first-line chemotherapy with CHOP plus L-asparaginase. Chemotherapy protocol was L-asparaginase (L-ASP) at 6000 IU/m2 D1~5 i.m. concomitant with standard CHOP every three weeks.Results: Patients had good tolerance to combination therapy of CHOP with L-asparaginase (A-CHOP). Two of our patients had stable disease, another five achieved complete remission, but two patients relapsed after five months and one year later, respectively. The response rate was 71% for A-CHOP treatment. No coagulation defect or bleeding tendency was found in each cycle of chemotherapy.Conclusions: All patients were well-tolerated to the A-CHOP regimen. But the additional effect of L-asparaginase in peripheral T-cell lymphoma treatment needs more studies to confirm it.

並列關鍵字

L-asparaginase ； peripheral T-cell lymphoma ； chemotherapy